Overview

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who did not respond to previous treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Mitsubishi Tanabe Pharma Corporation

Treatments:

Interferon-alpha
Peginterferon alfa-2b
Ribavirin